Biosynthesis approach of copper nanoparticles, physicochemical characterization, cefixime wastewater treatment, and antibacterial activities.

The aim of this paper is the green synthesis of copper nanoparticles (Cu NPs) via Quinoa seed extract. X-ray diffraction (XRD) results confirmed the production of the pure crystalline face center cubic system of the Cu NPs with an average crystallite size of 8.41 nm. Infrared spectroscopy (FT-IR) analysis confirmed the capping and stabilization of the Cu NPs bioreduction process. UV visible spectroscopy (UV-Vis). surface plasmon resonance revealed the absorption peak at 324 nm with an energy bandgap of 3.47 eV. Electrical conductivity was conducted assuring the semiconductor nature of the biosynthesized Cu NPs. Morphological analysis was investigated confirming the nano-characteristic properties of the Cu NPs as polycrystalline cubic agglomerated shapes in scanning electron microscopy (SEM) analysis. Transmission electron microscopy (TEM) analysis also was used to assess the cubic shapes at a particle size of 15.1 ± 8.3 nm and a crystallinity index about equal to 2.0. Energy dispersive spectroscopy (EDX) was conducted to investigate the elemental composition of the Cu NPs. As a potential utility of the biosynthesized Cu NPs as nano adsorbents to the removal of the Cefixime (Xim) from the pharmaceutical wastewater; adsorption studies and process parameters were being investigated. The following strategic methodology for maximum Xim removal was conducted to be solution pH 4, Cu NPs dosage 30 mg, Xim concentration 100 mg/L, and absolute temperature 313 K. The maximum monolayer adsorption capacity was 122.9 mg/g according to the Langmuir isothermal model, and the kinetic mechanism was pseudo-second-order. Thermodynamic parameters also were derived as spontaneous chemisorption endothermic processes. Antibacterial activity of the Xim and Xim@Cu NPs was investigated confirming they are highly potent against each Gram-negative and Gram-positive bacterium.

Hantzsch condensation reaction as a spectrofluorometric method for determination of alogliptin, an antidiabetic drug, in pure form, tablet form, and human and rat plasma.

To analyze alogliptin in its pharmaceutical dosage forms and human plasma, a sensitive, inexpensive, simple, and precise spectrofluorimetric method was developed and tested. This method was also used to investigate the drug's pharmacokinetic behaviour in the blood of rats. This was based on the Hantzsch reaction, which produces yellowish luminous products that can be detected spectrofluorometrically at 480 and 415 nm for emission and excitation, respectively, when the primary amine group in the examined drug reacts with acetylacetone and formaldehyde. Several experimental parameters that affect the reaction product's development and stability were explored and improved. The curve of fluorescence and concentration for alogliptin was linear in the concentration range 0.05-3.60 µg ml-1 . The proposed approach was validated according to International Council for Harmonization criteria. The method was successfully utilized to evaluate the examined drug in dose formulations and spiked human plasma with high accuracy.

A Glassy Carbon Electrode for the Determination of Linagliptin, an Antidiabetic Drug in Pure Form, Tablets and Some Biological Fluids by Adsorptive Stripping Voltammetry.

AIM: The present work provides a fast, simple, accurate, and inexpensive analytical method for the determination of Linagliptin (anti-diabetic drug). METHODS: The analysis was performed using a square wave adsorptive anodic stripping voltammetric technique (SWAASV) and glassy carbon electrode (GCE) as a working electrode. The experimental and instrumental parameters were studied and discussed to ensure the validity of the method. RESULTS: The method has a very good linearity (R2 = 0.9984), wide concentration range (0.189 - 2.268 µg mL-1), low detection limit of 0.052 µg mL-1 and low quantitation limit of 0.172 µg mL-1. CONCLUSION: Linagliptin was identified successfully using the proposed method in pharmaceutical formulations, spiked human urine and plasma with 99.67, 91.96, and 92.78% recovery, respectively, and the results obtained were compared with other reported methods.

Spectrofluorometric determination of alogliptin an antidiabetic drug in pure and tablet form using fluorescamine, a fluorogenic agent: application to content uniformity test.

Alogliptin is an antidiabetic drug that belongs to a group called dipeptidyl peptidase-4 enzyme inhibitors. As the drug contains a primary amino group in its structure, it readily reacts with fluorescamine in slightly alkaline medium (borate buffer, pH 8.8) to form a highly fluorescent product. Emission of this product was measured at 477 nm (λex = 387 nm). The linear range between the fluorescence intensity and the drug concentration was 0.1-0.5 µg ml-1 with a good correlation coefficient (0.9986). Limits of detection and quantitation were 22 and 72 ng ml-1 , respectively. Guidelines of the International Conference for Harmonisation were followed to validate the developed method with acceptable results. Alogliptin content was determined successfully in its commercial dosage form using the fluorescamine method with good recovery (98.60-101.26%). The method has excellent levels of accuracy and precision compared with the reported method as assessed using Student's t-test and Fisher's exact test. The method was applied successfully for the content uniformity test with high recovery and low relative standard deviation.